Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Mpox vaccine microneedle patch is a transdermal vaccine delivery system developed by CosMED Pharmaceutical for the prevention of Mpox (monkeypox) virus infection. The product utilizes CosMED's proprietary microneedle technology, which consists of microscopic needles that penetrate the stratum corneum to deliver vaccine antigens directly into the immunologically active layers of the skin. This approach is designed to elicit a robust immune response, potentially requiring lower doses of antigen than traditional injections (dose sparing). Additionally, the microneedle patch format offers advantages in terms of stability, ease of transport, and simplified administration, which are critical for responding to infectious disease outbreaks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mpox vaccine microneedle patch.